Literature research on TCM medication law of HBV-related hepatocirrhosis
YANG Xianzhao1,2 JIANG Feng2,3 RU Shuying2,4 ZHANG Peng2,3 LI Ying2,3 ZHANG Ludan2,3 YE Yong′an2,3
1.Department of Infectious Disease, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100700, China;
2.Institute of Liver Diseases, Beijing University of Chinese Medicine, Beijing 100700, China;
3.Department of Gastroenterology, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100700, China;
4.Department of Gastroenterology, Dongzhimen Hospital Eastern Affiliated to Beijing University of Chinese Medicine, Beijing 101100, China
Abstract：Objective To analyze the traditional Chinese medicine (TCM) medication law of HBV-related hepatocirrhosis based on the past clinical research literatures. Methods The clinical research literatures on TCM for HBV-related hepatocirrhosis from inception to September 2016 was searched in PubMed, Chinese biomedical literature database (CBM), China National Knowledge Infrastructure (CNKI), WanFang Data, VIP network. A database of TCM decoctions for HBV-related hepatocirrhosis was established. The frequency of medication was analyzed. The effect, nature and flavor of herbs were descriptively analyzed. Results A total of 118 articles were included. There were 121 prescriptions, 204 herbs and 1356 herb frequency involved. There were 11 herbs with a frequency greater than 30. The top 5 were Radix Astragali, Radix Salviae Miltiorrhizae, Carapax Trionycis, Rhizoma Atractylodis Macrocephalae and Radix Bupleuri. The 204 herbs could be divided into 19 categories according to the effect. The top 5 were deficiency-supplementing herb, blood-quickening stasis-transforming herb, heat-clearing herb, dampness-removing herb and qi-regulating herb, with a total frequency of 80.23%. In the frequency of herb nature, the top 3 were cold, warm and calm. The total frequency of cold herbs and slightly cold herbs was 37.75%. In the frequency of herb flavor, the top 3 were bitter, sweet and pungent. The frequency of bitter herbs was 32.40%. Conclusion The general rule of TCM in the treatment of HBV-related hepatocirrhosis is strengthening the body resistance and eliminating pathogenic factors. In the specific principle, on the basis of qi-boosting spleen-supplementing yin-nourishing therapy, blood-quickening stasis-transforming therapy, heat-clearing toxin-resolving therapy, dampness-clearing therapy and liver-coursing qi-rectifying therapy are often used in treating HBV-related hepatocirrhosis.
杨先照1,2 江锋2,3 茹淑瑛2,4 张鹏2,3 李莹2,3 张露丹2,3 叶永安2,3. 中医药治疗乙型肝炎肝硬化用药规律的文献研究[J]. 中国医药导报, 2017, 14(18): 157-160,180.
YANG Xianzhao1,2 JIANG Feng2,3 RU Shuying2,4 ZHANG Peng2,3 LI Ying2,3 ZHANG Ludan2,3 YE Yong′an2,3 . Literature research on TCM medication law of HBV-related hepatocirrhosis. 中国医药导报, 2017, 14(18): 157-160,180.
[1] Ott JJ，Stevens GA，Groeger J，et al. Global epidemiology of hepatitis B virus infection：new estimates of age-specific HBsAg seroprevalence and endemicity [J]. Vaccine，2012，30（12）：2212-2219.
[2] Lozano R，Naghavi M，Foreman K，et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010：a systematic analysis for the Global Burden of Disease Study 2010 [J]. Lancet，2013，380（9859）：2095-2128.
[3] Lu FM，Zhuang H. Management of hepatitis B in China [J]. Chin Med J（Engl），2009，122（1）：3-4.
[4] Goldstein ST，Zhou F，Hadler SC，et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact [J]. Int J Epidemiol，2005，34（6）：1329-1339.
[5] Wang FS，Fan JG，Zhang Z，et al. The global burden of liver disease：the major impact of China [J]. Hepatology，2014， 60（6）：2099-2108.
[6] 王贵强，王福生，成军，等.《慢性乙型肝炎防治指南》（2015更新版）[J].中华肝脏病杂志，2015，21（12）：219-240.
[7] 国家药典委员会.中国药典[M].一部.北京：中国医药科技出版社，2015.
[8] 凌耀星.难经校注[M].北京：人民卫生出版社，1991：97.
[9] 罗仁，曹文富.中医内科学[M].北京：科学出版社，2012：273-274.
[10] 尹常健，李勇.对乙型肝炎中医病因病机学的再认识[J].中医杂志，1993，34（7）：431-433.
[11] 刘成海，刘平，胡义扬，等.中医药抗肝纤维化临床与基础研究进展[J].世界科学技术：中医药现代化，2007，9（2）：112-119.
[12] 袁虹，曹廷智，刘红，等.302例乙型肝炎肝硬化患者中医证候学探讨[J].中西医结合肝病杂志，2009，19（6）：346-349.
[13] 张琴，刘平，章浩伟，等.900例肝炎后肝硬化中医证候判别模式的研究[J].中国中西医结合杂志，2006，26（8）：694-697.
[14] 王岭，张均倡，张朴，等.肝硬化的形态学变化及其与中医证候要素关系的探讨[J].中西医结合肝病杂志，2006， 16（1）：4-7.
[15] 李毅，刘艳，寇小妮，等.乙肝后肝硬化症状学聚类研究[J].中医药导报，2012，18（2）：14-16.
[16] 谭春雨，刘平.肝硬化“虚损生积”病机理论溯源及其临床意义[J].上海中医药大学学报，2010，24（4）：25-28.
[17] 慕永平，刘成海，张华，等.肝硬化“虚损生积”论——刘平教授学术思想浅析[J].上海中医药大学学报，2013， 27（2）：1-4.
[18] 张华，刘平.基于黄芪汤益气效应解析代偿期乙肝肝硬化的“虚损”病机理论[J].世界科学技术：中医药现代化，2016，18（11）：1833-1838.
[19] 段志军，李吉彦，谭晨，等.益气软肝方抗肝纤维化的实验研究[J].中国中西医结合消化杂志，2007，15（5）：316-319.
[20] 段志军，李吉彦，谭晨，等.益气软肝方与肝刺激因子对大鼠免疫性肝纤维化保护作用的对照研究[J].中医杂志，2003，44（5）：374-376.
2017, Vol. 14 
京公网安备 11010502046598号